Literature DB >> 33405268

Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement.

Douglas R Sidell1,2, Karthik Balakrishnan1,2, Simon R Best3, Karen Zur4, Julia Buckingham5, Alessandro De Alarcon6, Fuad M Baroody7, Jonathan M Bock8, Emily F Boss9, Charles M Bower10, Paolo Campisi11, Sharon F Chen12, Jeffrey M Clarke13, Kevin D Clarke14, Alejandro Cocciaglia15, Robin T Cotton6, Giselle Cuestas16, Kara L Davis17, Victor H DeFago18, Frederik G Dikkers19, Ines Dossans20, Walter Florez21, Elizabeth Fox22, Aaron D Friedman23, Nazaneen Grant24, Osama Hamdi25, Norman D Hogikyan26, Kaalan Johnson27, Liane B Johnson28, Romaine F Johnson29, Peggy Kelly30, Adam M Klein31, Claire M Lawlor32, Nicolas Leboulanger33, Alejandro G Levy34, Derek Lam35, Greg R Licameli36, Steve Long37, David G Lott38, Dayse Manrique39, James Scott McMurray40, Kara D Meister1,2, Anna H Messner41, Michael Mohr42, Pamela Mudd32, Anthony J Mortelliti43, Daniel Novakovic44, Julian Ongkasuwan45, Shazia Peer46, Krysztof Piersiala47, Jeremy D Prager30, Seth M Pransky48, Diego Preciado32, Tiffany Raynor49, Rico N P M Rinkel50, Hugo Rodriguez51, Verónica P Rodríguez16, John Russell52, María Laura Scatolini51, Patrick Scheffler1, David F Smith53, Lee P Smith54, Marshall E Smith55, Richard J H Smith56, Abraham Sorom57, Amalia Steinberg58, John A Stith59, Dana Thompson60, Jerome W Thompson61, Patricio Varela62, David R White63, Andre M Wineland9, Christina J Yang64, Carlton J Zdanski65, Craig S Derkay66.   

Abstract

OBJECTIVES/HYPOTHESIS: The purpose of this study is to develop consensus on key points that would support the use of systemic bevacizumab for the treatment of recurrent respiratory papillomatosis (RRP), and to provide preliminary guidance surrounding the use of this treatment modality. STUDY
DESIGN: Delphi method-based survey series.
METHODS: A multidisciplinary, multi-institutional panel of physicians with experience using systemic bevacizumab for the treatment of RRP was established. The Delphi method was used to identify and obtain consensus on characteristics associated with systemic bevacizumab use across five domains: 1) patient characteristics; 2) disease characteristics; 3) treating center characteristics; 4) prior treatment characteristics; and 5) prior work-up.
RESULTS: The international panel was composed of 70 experts from 12 countries, representing pediatric and adult otolaryngology, hematology/oncology, infectious diseases, pediatric surgery, family medicine, and epidemiology. A total of 189 items were identified, of which consensus was achieved on Patient Characteristics (9), Disease Characteristics (10), Treatment Center Characteristics (22), and Prior Workup Characteristics (18).
CONCLUSION: This consensus statement provides a useful starting point for clinicians and centers hoping to offer systemic bevacizumab for RRP and may serve as a framework to assess the components of practices and centers currently using this therapy. We hope to provide a strategy to offer the treatment and also to provide a springboard for bevacizumab's use in combination with other RRP treatment protocols. Standardized delivery systems may facilitate research efforts and provide dosing regimens to help shape best-practice applications of systemic bevacizumab for patients with early-onset or less-severe disease phenotypes. LEVEL OF EVIDENCE: 5 Laryngoscope, 131:E1941-E1949, 2021.
© 2021 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Avastin; Systemic bevacizumab; consensus

Mesh:

Substances:

Year:  2021        PMID: 33405268      PMCID: PMC9034687          DOI: 10.1002/lary.29343

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   2.970


  15 in total

1.  Standardized outcome and reporting measures in pediatric head and neck lymphatic malformations.

Authors:  Karthik Balakrishnan; Nancy Bauman; Robert H Chun; David H Darrow; J Fredrik Grimmer; Jonathan A Perkins; Gresham T Richter; Jennifer J Shin; Giridhar M Shivaram; Douglas R Sidell; Ravindhra G Elluru
Journal:  Otolaryngol Head Neck Surg       Date:  2015-03-31       Impact factor: 3.497

2.  Outcome measures for pediatric laryngotracheal reconstruction: International consensus statement.

Authors:  Karthik Balakrishnan; Douglas R Sidell; Nancy M Bauman; Gaston F Bellia-Munzon; R Paul Boesch; Matthew Bromwich; Shelagh A Cofer; Cori Daines; Alessandro de Alarcon; Nöel Garabedian; Catherine K Hart; Jonathan B Ida; Nicolas Leboulanger; Peter B Manning; Deepak K Mehta; Philippe Monnier; Charles M Myer; Jeremy D Prager; Diego Preciado; Evan J Propst; Reza Rahbar; John Russell; Michael J Rutter; Briac Thierry; Dana M Thompson; Michele Torre; Patricio Varela; Shyan Vijayasekaran; David R White; Andre M Wineland; Robert E Wood; Christopher T Wootten; Karen Zur; Robin T Cotton
Journal:  Laryngoscope       Date:  2018-08-27       Impact factor: 3.325

3.  Systemic bevacizumab for recurrent respiratory papillomatosis: A national survey.

Authors:  Simon R Best; Michael Mohr; Karen B Zur
Journal:  Laryngoscope       Date:  2017-06-28       Impact factor: 3.325

4.  The cost of juvenile-onset recurrent respiratory papillomatosis.

Authors:  D Bishai; H Kashima; K Shah
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2000-08

5.  Quality of life of patients with recurrent respiratory papillomatosis.

Authors:  Michel R M San Giorgi; Leena-Maija Aaltonen; Heikki Rihkanen; Robin E A Tjon Pian Gi; Bernard F A M van der Laan; Josette E H M Hoekstra-Weebers; Frederik G Dikkers
Journal:  Laryngoscope       Date:  2016-11-15       Impact factor: 3.325

6.  Bevacizumab chemotherapy for management of pulmonary and laryngotracheal papillomatosis in a child.

Authors:  Karen B Zur; Elizabeth Fox
Journal:  Laryngoscope       Date:  2016-12-20       Impact factor: 3.325

7.  Local injection of bevacizumab (Avastin) and angiolytic KTP laser treatment of recurrent respiratory papillomatosis of the vocal folds: a prospective study.

Authors:  Steven M Zeitels; Anca M Barbu; Tali Landau-Zemer; Gerardo Lopez-Guerra; James A Burns; Aaron D Friedman; Mason W Freeman; Yuan-Di Halvorsen; Robert E Hillman
Journal:  Ann Otol Rhinol Laryngol       Date:  2011-10       Impact factor: 1.547

8.  [Treatment of respiratory papillomatosis--a case report on systemic treatment with bevacizumab].

Authors:  S Nagel; C Busch; T Blankenburg; W Schütte
Journal:  Pneumologie       Date:  2009-07-09

9.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

Review 10.  Airway Papillomatosis: New Treatments for an Old Challenge.

Authors:  Nankee Kumar; Diego Preciado
Journal:  Front Pediatr       Date:  2019-09-18       Impact factor: 3.418

View more
  4 in total

1.  Outcomes After Human Papillomavirus Vaccination in Patients With Recurrent Respiratory Papillomatosis: A Nonrandomized Clinical Trial.

Authors:  Jana Smahelova; Eva Hamsikova; Viera Ludvikova; Jitka Vydrova; Joseph Traboulsi; Ondrej Vencalek; Petr Lukeš; Ruth Tachezy
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2022-07-01       Impact factor: 8.961

2.  Use of cryotherapy to treat obstructing papilloma of an accessory tracheal bronchus: case report.

Authors:  Alexandra E Adams; Federico A Steiner
Journal:  J Cardiothorac Surg       Date:  2022-10-22       Impact factor: 1.522

Review 3.  Recurrent respiratory papillomatosis: A 2020 perspective.

Authors:  Jacob J Benedict; Craig S Derkay
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-03-13

4.  Application of Bevacizumab Combined With Chemotherapy in Patients With Colorectal Cancer and Its Effects on Brain-Gut Peptides, Intestinal Flora, and Oxidative Stress.

Authors:  Chao Chen; Songtao Hou; Fei Zhao; Bin Wu; Tingting Liu; Zhao Zhang; Yuwei Li; Hongchao Li
Journal:  Front Surg       Date:  2022-04-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.